Abstract:
PURPOSE: A method for screening a gene which characteristically developing aging is provided to control gene expression and to suppress aging on the skin. CONSTITUTION: A method for screening a gene associated with skin aging comprises: a step of extracting total RNA from skin tissue and performing microarray; a step of analyzing genes which are changed by aging using bioinformatics; a step of selecting a candidate gene relating to skin aging; and a step of determining a candidate gene. The skin aging includes intrinsic aging or menopause aging.
Abstract:
PURPOSE: A composition for skin whitening containing a material which suppresses expression or activation of alpha-synuclein gene is provided to ensure skin whitening activity without citotoxicity. CONSTITUTION: A composition for skin whitening contains a material which suppresses expression or activation of alpha-synuclein gene. A pharmaceutical composition for skin whitening contains the composition. The alpha-synuclein gene encodes alpha-synuclein protein with an amino acid sequence of sequence number 1. The alpha-synuclein gene has a base sequence of sequence number 2. The material is an antibody or antibody fragment which specifically binds to the protein.
Abstract:
PURPOSE: A composition for treating inflammatory diseases is provided to control inflammation through controlling expression and activation ABH antigen and to prevent or treat aging. CONSTITUTION: A composition for treating inflammation contains ABH antigen or a material controlling the expression of ABH antigen as an active ingredient. The inflammatory diseases are inflammatory dermatitis or inflammatory diseases of intestine, stomach, or gullet. The material controlling the expression of ABH antigen is ABO, FUT1 or FUT2 gene.
Abstract:
PURPOSE: A biomarker of which expression is specifically decreased or suppressed in the sensitive skin is provided to quickly diagnose sensitive skin and used for screening a relieving agent. CONSTITUTION: A biomarker for diagnosing sensitive skin contains gene of which expression is decreased or increased in the sensitive skin compared to healthy skin or a protein encoding the gene. A method for screening a relieving agent of sensitivity comprises: a step of conjugating a candidate agent to a protein encoded by a gene of which expression is increased or decreased in the sensitive skin; and a step of confirming the suppression of protein activity.